• Ac-YVAD-CMK for Kupffer Cell Inflammation

  2026-09-01

  Ac-YVAD-CMK is a selective, irreversible caspase-1 probe for separating cytokine maturation and pyroptotic injury from TMEM16F-dependent membrane repair. This practical workflow applies the compound to Kupffer cell and Listeria monocytogenes studies while emphasizing controls, washout designs, and interpretation limits.

• SM-164 and Signalosome-Aware Apoptosis Assays

  2026-09-01

  SM-164 is a bivalent Smac mimetic that enables precise investigation of IAP-controlled, TNFα-dependent apoptosis. This guide shows how to pair its molecular pharmacology with signalosome-aware controls for more rigorous cancer research and caspase activation assays.

• Berberine Inhibits SASP Inflammation via RXRα/PPARγ

  2026-08-31

  This 2025 reference study identifies an RXRα/PPARγ/NEDD4 pathway through which berberine suppresses SASP-related inflammation in atherosclerosis. Its combination of transcriptomic analysis, foam-cell models, plaque phenotyping, and macrophage-specific RXRα knockdown provides a mechanistic framework for testing how nuclear-receptor signaling regulates senescent vascular inflammation.

• Deferasirox, Mitochondrial ROS, and Myeloid Fate

  2026-08-30

  Jeffries and colleagues show that deferasirox affects myeloid maturation in a stage-dependent manner, linking mitochondrial reactive oxygen species with altered NF-κB, MYC, and PU.1 transcriptional programs. The findings help reconcile conflicting reports about deferasirox in hematopoietic cells and provide a framework for studying how iron chelation may influence myelopoiesis beyond systemic iron removal.

• Deferasirox Fe3+ chelate Workflow Guide

  2026-08-29

  Build reproducible iron overload and myeloid differentiation assays with a defined ferric deferasirox complex, while separating chelate exposure from apo-chelator biology. This guide combines practical solvent handling, oxygen-sensitive ROS measurements, and controls informed by recent NF-κB research.

• ML385: NRF2 Inhibition in Cancer and Redox Research

  2026-08-29

  ML385 is a selective NRF2 inhibitor for dissecting antioxidant signaling, non-small cell lung cancer resistance, and redox-dependent phenotypes. This workflow combines dose–response testing with target-engagement and functional assays, while extending the compound’s use to NRF2-dependent inflammatory osteolysis research.

• Staurosporine Workflows for Kinase and Cancer Research

  2026-08-28

  Build more informative kinase, apoptosis, migration, and angiogenesis assays with Staurosporine, a broad-spectrum perturbation tool rather than a pathway-specific inhibitor. This workflow shows how to separate cytotoxicity from signaling effects while applying recent TNBC metastasis findings to practical experimental design.

• GSDMC Drives Stemness and Immune Evasion in PDAC

  2026-08-28

  The reference study identifies Gasdermin C (GSDMC) as a nuclear transcriptional regulator of pancreatic ductal adenocarcinoma rather than only a pyroptosis-associated pore-forming protein. Its findings connect ADAM17-dependent cleavage, cancer stemness, metastasis, and CXCL9-linked immune evasion, suggesting a route to improve responses to KRAS^G12D inhibition and PD-1 blockade.

• GSDMC Drives Stemness and Immune Evasion in PDAC

  2026-08-27

  A 2024 Advanced Science study identifies Gasdermin C as a nuclear regulator of pancreatic ductal adenocarcinoma stemness, metastasis, and immune evasion rather than merely a pyroptosis-associated pore-forming protein. The work connects ADAM17-dependent GSDMC cleavage to CXCL9-mediated immune remodeling and improved responses to KRASG12D inhibition and PD-1 blockade in preclinical models.

• Dual-Action Inhibitors Reprogram p38α Dephosphorylation

  2026-08-27

  The reference preprint shows that selected kinase inhibitors can do more than occupy the p38α active site: they can also accelerate WIP1-mediated removal of the activation-loop phosphate. Biochemical assays and X-ray structures connect this effect to an inhibitor-stabilized activation-loop conformation, offering a mechanistic framework for interpreting p38 inhibitor potency and selectivity.

• Nutlin-3a and the p53–Ferroptosis Frontier

  2026-08-26

  Nutlin-3a is more than a conventional MDM2 inhibitor: it is a controllable chemical probe for testing how p53 pathway activation intersects with cell-cycle control, apoptosis, and ferroptosis. This thought-leadership perspective connects MDM2–p53 biology with the miR-18a–ALOXE3 axis in glioblastoma and offers a practical framework for translational validation, biomarker selection, and model design.

• PD0325901: A MEK-to-Embryo Assay Framework

  2026-08-26

  PD0325901 is a selective MEK inhibitor for dissecting ERK signaling, proliferation, and apoptosis. This article develops a cautious assay framework linking pharmacologic pathway perturbation with WDR36-dependent glycolytic control of trophectoderm development.

• BIBR 1532: A Telomerase Assay Strategy

  2026-08-25

  BIBR 1532 is a selective telomerase inhibitor that connects hTERT inhibition with telomere-state and leukemia-cell fate measurements. This article presents a staged assay strategy and explains how recent CF10–EdU findings can improve interpretation without conflating telomere attrition with direct telomerase inhibition.

• CA-074 Workflow for Cathepsin B Mechanisms

  2026-08-25

  CA-074 combines nanomolar cathepsin B potency with strong selectivity, making it useful for separating CTSB-dependent effects from broader lysosomal protease activity. This guide translates the compound into practical necroptosis, cancer metastasis, neurotoxicity, and immune response workflows, with assay controls and troubleshooting strategies.

• I-BET151: BET Inhibition Workflow Guide

  2026-08-24

  Build reproducible I-BET151 experiments around BET-dependent transcription, apoptosis, and cell-cycle phenotypes. This guide also shows how to translate super-enhancer and SLC7A11 findings into a hypothesis-driven prostate cancer workflow without overstating what the reference study directly proved.

451 records 6/31 page Previous Next First page 上5页 678910 下5页 Last page